Peter Kaiser is Chief Development Officer at OCULAR THERAPEUTIX, INC (OCUL). They have made 10 open-market trades across 1 company since 2024, most recently 2026-10-02.
CIK 0002011869
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OCUL | 254,388 | $1.8M |
Shares reported on the most recent Form 4, priced at the 2026-10-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OCUL | SELL | 2026-10-02 | 2026-10-06 | $7.05 | $70K | -5.5% | — | — |
| OCUL | SELL | 2026-08-24 | 2026-08-26 | $10.77 | $33K | +6.5% | -9.8% | — |
| OCUL | SELL | 2026-05-26 | 2026-05-28 | $8.20 | $24K | -8.1% | +7.6% | +17.0% |
| OCUL | SELL | 2026-02-23 | 2026-02-25 | $8.28 | $23K | +5.6% | -19.6% | -11.8% |
| OCUL | SELL | 2025-11-24 | 2025-11-26 | $12.02 | $36K | +31.3% | +3.4% | -26.3% |
| OCUL | SELL | 2025-10-02 | 2025-10-06 | $11.03 | $213K | +11.4% | -1.3% | +5.4% |
| OCUL | SELL | 2025-08-25 | 2025-08-27 | $12.04 | $36K | +3.6% | +1.7% | -1.5% |
| OCUL | SELL | 2025-05-23 | 2025-05-27 | $7.17 | $21K | +29.8% | +36.1% | +70.8% |
| OCUL | SELL | 2025-02-24 | 2025-02-26 | $6.87 | $21K | +11.0% | +10.0% | +0.7% |
| OCUL | SELL | 2024-11-25 | 2024-11-27 | $9.01 | $26K | -6.3% | -16.3% | -32.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.